Breaking News

A multi-region analysis of colorectal cancers suggests samples from opposite sides of a tumor can help trace early, invasiveness-related tumor characteristics.

PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.

Last week, GenomeWeb's readers were most interested in Illumina Ventures' new investment in Luna DNA.

Genome-wide association study hits can uncover potential therapies for conditions like inflammatory bowel disease, a Biology of Genomes speaker said.

Researchers used CRISPR-Cas9 screening assays in mouse and human cells to track down point mutations in the PARP1 gene that boost resistance to PARP inhibitor drugs.

Baylor College of Medicine's Olga Dudchenko sad the approach could assemble de novo mammalian genomes for less than $1,000.

The revenue increase was primarily driven by collaborative development services activities with partners including Qiagen.

A study of more than 5,000 breast cancer patients found that multi-gene sequencing has rapidly replaced BRCA1/2-only tests, resulting in better pathogenic variant detection but also higher VUS rates.

Dramatic genetic diversity in Mycobacterium leprae isolates from medieval Europe could point to a long history or potential origins on the continent.

The award will go toward development of Talis Bio's SlipChip POC technology for pathogen identification and antibiotic-susceptibility testing.